Erlosamide
Erlosamide is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sodium channel protein type 9 subunit alpha. In addition, it is known to target sodium channel protein type 2 subunit alpha, sodium channel protein type 3 subunit alpha, and sodium channel protein type 10 subunit alpha.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lacosamide oral solution | ANDA | 2023-06-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
100 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 8 | 24 | 3 | 6 | 40 |
| Partial epilepsies | D004828 | EFO_0004263 | — | 3 | 5 | 4 | 2 | 13 | |
| Seizures | D012640 | G40.4 | — | 1 | 2 | 1 | 2 | 5 | |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 5 | 6 | — | — | 9 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 1 | — | — | 2 |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | — | 1 | — | — | 1 |
| Dementia | D003704 | F03 | — | — | 1 | — | — | 1 | |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Depression | D003863 | F33.9 | — | — | 1 | — | — | 1 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Small fiber neuropathy | D000071075 | — | — | 1 | — | — | 1 | ||
| Sciatica | D012585 | HP_0011868 | M54.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 1 | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | 1 | 2 | |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | — | — | — | 2 |
| Postherpetic neuralgia | D051474 | — | 2 | — | — | — | 2 | ||
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 | |
| Peripheral nervous system diseases | D010523 | G64 | — | 1 | — | — | — | 1 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 1 | — | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | — | — | — | 1 |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 7 | — | — | — | — | 7 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | 1 | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Chronic pain | D059350 | HP_0012532 | 1 | — | — | — | — | 1 | |
| Hyperalgesia | D006930 | 1 | — | — | — | — | 1 | ||
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | 1 | — | — | — | — | 1 |
| Endoscopic retrograde cholangiopancreatography | D002760 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | 1 | 1 | ||
| Partial epilepsy motor | D020938 | EFO_1001089 | — | — | — | — | 1 | 1 | |
| Traumatic brain injuries | D000070642 | S06 | — | — | — | — | 1 | 1 | |
| Breast feeding | D001942 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ERLOSAMIDE |
| INN | lacosamide |
| Description | Lacosamide is a N-acyl-amino acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 175481-36-4 |
| RxCUI | 623400 |
| ChEMBL ID | CHEMBL58323 |
| ChEBI ID | — |
| PubChem CID | 219078 |
| DrugBank | DB06218 |
| UNII ID | 563KS2PQY5 (ChemIDplus, GSRS) |
Target
Agency Approved
SCN9A
SCN9A
Organism
Homo sapiens
Gene name
SCN9A
Gene synonyms
NENA
NCBI Gene ID
Protein name
sodium channel protein type 9 subunit alpha
Protein synonyms
hNE-Na, Neuroendocrine sodium channel, Peripheral sodium channel 1, PN1, Sodium channel protein type IX subunit alpha, sodium channel, voltage-gated, type IX, alpha polypeptide, sodium channel, voltage-gated, type IX, alpha subunit, voltage-gated sodium channel alpha subunit Nav1.7, Voltage-gated sodium channel subunit alpha Nav1.7
Uniprot ID
Mouse ortholog
Scn9a (20274)
sodium channel protein type 9 subunit alpha (Q62205)
Alternate
SCN2A
SCN2A
SCN3A
SCN3A
SCN10A
SCN10A
Organism
Homo sapiens
Gene name
SCN2A
Gene synonyms
NAC2, SCN2A1, SCN2A2
NCBI Gene ID
Protein name
sodium channel protein type 2 subunit alpha
Protein synonyms
HBSC II, Sodium channel protein brain II subunit alpha, Sodium channel protein type II subunit alpha, sodium channel protein, brain type 2 alpha subunit, sodium channel, voltage-gated, type II, alpha 1 polypeptide, sodium channel, voltage-gated, type II, alpha 2 polypeptide, sodium channel, voltage-gated, type II, alpha subunit, voltage-gated sodium channel subtype II, Voltage-gated sodium channel subunit alpha Nav1.2, voltage-gated sodium channel type II alpha subunit
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,379 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,933 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more